On September 15, 2023, momelotinib (JAK1/2 and ACVR1 inhibitor) received FDA approval as a treatment for patients with intermediate- or high-risk MF and anemia based on the findings of the phase 3 trials, MOMENTUM (NCT04173494) and SIMPLIFY-1 (NCT01969838). This evidence concerns the gene JAK1 and anemia.